UK Regulators Approve Clinical Trial for PX578
The UK Medicines and Healthcare products Regulatory Agency has cleared a trial for the potential POLG disease treatment.
Updated on Oct. 31, 2026 in Biotech
Live Poll
Are pharmaceutical companies moving fast enough to provide effective treatments for rare, life-threatening genetic diseases?
The UK Medicines and Healthcare products Regulatory Agency has authorized a clinical trial application for PX578, a small molecule activator designed to treat POLG-mediated primary mitochondrial disorders. This follows recent regulatory clearances in the United States.
Why it matters
PX578 is being developed to restore mitochondrial function and modify the underlying disease process in patients with POLG disease, for which there are currently no approved disease-modifying therapies.
PX578 acts as a small molecule activator of the mitochondrial polymerase POLG to increase mitochondrial DNA levels. The drug is targeted at addressing a progressive genetic disorder currently lacking approved disease-modifying therapies.
The players
Pretzel Therapeutics
This biotechnology company is the developer of the small molecule candidate PX578.
UK Medicines and Healthcare products Regulatory Agency
This is the executive agency responsible for ensuring that medicines and medical devices work and are acceptably safe.
US Food and Drug Administration
This federal agency is responsible for protecting public health by regulating human drugs and biological products.
The details
The drug is set to be evaluated in the randomized, double-blind, placebo-controlled phase 2 POLARIS study. Researchers aim to use this trial to assess the candidate's ability to restore mitochondrial function in patients.
Timeline
August 2026: The US FDA cleared the Investigational New Drug application for PX578.
September 2026: The US FDA granted Fast Track Designation to the drug candidate.
October 31, 2026: The UK Medicines and Healthcare products Regulatory Agency authorized the clinical trial application.
Year-end 2026: Pretzel Therapeutics plans to initiate the phase 2 POLARIS study.
The Big Picture
The development of PX578 follows the structural framework of the FDA Fast Track Designation program, which seeks to accelerate the review of drugs intended for serious conditions. This authorization reflects a growing industry trend toward using targeted small molecule activators to address rare genetic mutations.
This regulatory clearance marks a significant step toward developing potential treatment options for patients suffering from currently untreatable primary mitochondrial disorders. Future trial results will be essential in determining if the drug can safely restore mitochondrial function.
The takeaway
The authorization of this trial represents a critical milestone in the effort to find a disease-modifying therapy for POLG disease. Patients and families affected by mitochondrial disorders will be monitoring the upcoming phase 2 study results for signs of efficacy.
What happens next
Pretzel Therapeutics is scheduled to initiate the phase 2 POLARIS study by the end of 2026.
Further reading
Learn more about the evolving landscape of medical research in the Biotech section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Are pharmaceutical companies moving fast enough to provide effective treatments for rare, life-threatening genetic diseases?
